EBC biomarkers and cough in IPF
Research type
Research Study
Full title
Exhaled breath condensate biomarkers and cough in people with idiopathic pulmonary fibrosis
IRAS ID
152379
Contact name
Andrew Wilson
Contact email
Sponsor organisation
University of East Anglia
Duration of Study in the UK
0 years, 9 months, 28 days
Research summary
Idiopathic Pulmonary Fibrosis (IPF) is a progressive and incurable disease resulting in lung fibrosis. Patients often suffer from a chronic cough. The cough may be caused by the production of substances called reactive oxygen species (sometime called "free radicals") in the lungs. We can measure these by capturing the moisture in exhaled breath. We wish to compare the levels of these substances to the severity of cough that they may have.
Therefore, EBC hydrogen peroxide may potentially be used as a biomarker to predict response to therapy in patients with IPF. We would like to evaluate whether hydrogen peroxide concentrations measured in EBC correlates with disease severity of IPF. Additionally, if subgroups of IPF patients are found to have increased levels of hydrogen peroxide, these patients may demonstrate improved response to particular forms of therapy e.g. anti oxidant therapy.REC name
South Central - Hampshire B Research Ethics Committee
REC reference
15/SC/0614
Date of REC Opinion
12 Oct 2015
REC opinion
Further Information Favourable Opinion